Mangoceuticals (NASDAQ:MGRX) Issues Quarterly Earnings Results

Mangoceuticals (NASDAQ:MGRX) posted its quarterly earnings results on Tuesday. The company reported ($0.22) EPS for the quarter, FiscalAI reports. The company had revenue of $0.07 million during the quarter. Mangoceuticals had a negative return on equity of 106.57% and a negative net margin of 4,639.13%.

Mangoceuticals Trading Up 3.4%

Shares of Mangoceuticals stock opened at $0.43 on Thursday. The firm has a market cap of $7.25 million, a P/E ratio of -0.29 and a beta of 2.12. Mangoceuticals has a 12 month low of $0.16 and a 12 month high of $2.75. The stock’s fifty day moving average price is $0.38 and its 200-day moving average price is $0.69.

Analyst Ratings Changes

Several brokerages have recently commented on MGRX. Weiss Ratings restated a “sell (e+)” rating on shares of Mangoceuticals in a research note on Friday, March 27th. Wall Street Zen upgraded Mangoceuticals to a “sell” rating in a research note on Saturday, April 25th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Mangoceuticals has an average rating of “Sell”.

Hedge Funds Weigh In On Mangoceuticals

Several institutional investors have recently made changes to their positions in MGRX. Geode Capital Management LLC increased its stake in shares of Mangoceuticals by 35.4% during the second quarter. Geode Capital Management LLC now owns 26,498 shares of the company’s stock valued at $40,000 after buying an additional 6,928 shares during the period. Jane Street Group LLC purchased a new position in Mangoceuticals in the fourth quarter valued at about $35,000. Armistice Capital LLC purchased a new position in Mangoceuticals in the fourth quarter valued at about $1,137,000. Boothbay Fund Management LLC purchased a new position in Mangoceuticals in the fourth quarter valued at about $28,000. Finally, Ikarian Capital LLC purchased a new position in Mangoceuticals in the fourth quarter valued at about $102,000. Hedge funds and other institutional investors own 56.72% of the company’s stock.

Mangoceuticals Company Profile

Mangoceuticals, Inc develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program.